Zollinger‑Ellison syndrome secondary to MEN1 - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Zollinger‑Ellison Syndrome Secondary to MEN1 – Complete Medical Guide

Zollinger‑Ellison Syndrome Secondary to MEN1

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum, causing excessive gastric acid secretion. When ZES occurs as part of the hereditary condition multiple endocrine neoplasia type 1 (MEN 1), it is termed “ZES secondary to MEN1.”

  • Prevalence of ZES: Approximately 0.1–1 case per million people worldwide.1
  • MEN 1 prevalence: 1–10 per 100,000 persons; 10–30 % of MEN 1 patients develop gastrinomas that result in ZES.2
  • Typical age of onset: Gastrinomas in MEN 1 appear in the third–fourth decade; ZES symptoms usually manifest between ages 30‑50.
  • Gender: Both sexes are equally affected, though MEN 1 tends to be diagnosed slightly more often in women because of earlier detection of hyperparathyroidism.

Symptoms

Excess gastrin drives the parietal cells of the stomach to secrete large volumes of acid, which overwhelms the protective mechanisms of the upper gastrointestinal (GI) tract. Symptoms may be intermittent at first and become more constant as the disease progresses.

Gastro‑intestinal (GI) symptoms

  • Recurrent peptic ulcers: Ulcers may be multiple, >3 cm, or located in atypical sites (e.g., jejunum, ileum).
  • Abdominal pain: Burning or cramping pain that worsens 1–2 hours after meals.
  • Diarrhea: Occurs in 30‑50 % of patients; volume can be >5 L/day in severe cases.
  • Steatorrhea (fatty stools): Malabsorption due to acid inactivation of pancreatic enzymes.
  • Nausea & vomiting: May be triggered by large meals or alcohol.
  • Weight loss: Result of malabsorption, chronic pain, and reduced food intake.

Systemic symptoms

  • Fatigue & weakness: From chronic anemia (often iron deficiency due to ulcer bleeding) and nutrient malabsorption.
  • Osteoporosis: Long‑term acid excess can impair calcium absorption, especially when combined with MEN 1‑related hyperparathyroidism.
  • Recurrent anemia: Chronic blood loss from ulcers.

MEN 1‑related manifestations (may coexist)

  • Primary hyperparathyroidism (most common MEN 1 feature).
  • Pituitary adenomas (prolactinoma, growth‑hormone–secreting tumors).
  • Pancreatic neuroendocrine tumors (insulinoma, glucagonoma) besides gastrinomas.

Causes and Risk Factors

Underlying Mechanism

ZES secondary to MEN1 is caused by a germline mutation in the MEN1 tumor suppressor gene located on chromosome 11q13. The MEN1 gene encodes menin, a protein involved in DNA repair and regulation of cell growth. Loss‑of‑function mutations lead to unchecked proliferation of neuroendocrine cells, most often in the duodenum or pancreas, producing gastrin.

Risk Factors

  • Family history of MEN 1: Autosomal‑dominant inheritance gives each first‑degree relative a 50 % chance of carrying the mutation.
  • Known MEN1 gene mutation: Even asymptomatic carriers should undergo regular screening.
  • Other endocrine tumors: Presence of hyperparathyroidism or a pituitary adenoma raises suspicion for MEN 1 and warrants gastrin testing.
  • Age: While gastrinomas can occur at any age, MEN 1‑related tumors typically present before age 50.

Diagnosis

Diagnosing ZES in the setting of MEN1 involves confirming hypergastrinemia, ruling out other causes of high gastrin, and identifying the tumor(s). A multidisciplinary team—gastroenterology, endocrinology, radiology, and pathology—is usually required.

Laboratory Tests

  • Fasting serum gastrin: Levels >1000 pg/mL (10‑fold the upper limit) are highly suggestive. Even modest elevations (200–1000 pg/mL) are significant if the gastric pH is <2.
  • Secretin stimulation test: Intravenous secretin paradoxically raises gastrin >120 pg/mL in ZES (positive in >90 % of cases).3
  • Calcium and parathyroid hormone (PTH): Elevated in MEN 1‑related hyperparathyroidism.
  • Genetic testing: Sequencing of the MEN1 gene confirms hereditary disease; recommended for patients with a family history or multiple MEN1 manifestations.

Imaging Studies

  • Endoscopic ultrasound (EUS): High‑resolution view of the pancreas and duodenum; can detect lesions <5 mm.
  • Multiphasic contrast‑enhanced CT or MRI: Provides anatomical detail and assesses liver metastases.
  • Somatostatin receptor imaging (Ga‑68 DOTATATE PET/CT): Most sensitive for neuroendocrine tumors, especially small duodenal gastrinomas.
  • Selective arterial secretagogue injection (SASI) test: Rarely used; helps localize gastrin‑secreting tissue when non‑invasive imaging is inconclusive.

Diagnostic Criteria for ZES secondary to MEN1

  1. Fasting gastrin >1000 pg/mL OR gastrin >200 pg/mL with gastric pH < 2 plus a positive secretin test.
  2. Radiologic or endoscopic evidence of a gastrinoma (duodenal or pancreatic).
  3. Presence of a pathogenic MEN1 germline mutation or ≥2 other MEN1‑associated tumors.

Treatment Options

Therapy aims to control acid hypersecretion, remove or control tumor growth, and manage other MEN 1 manifestations.

Acid‑Suppressive Medications

  • High‑dose proton‑pump inhibitors (PPIs): Omeprazole 60–80 mg/day, rabeprazole 20–40 mg/day, or equivalent. PPIs are the mainstay; they heal ulcers and relieve symptoms in >90 % of patients.4
  • Histamine‑2 receptor antagonists (H2RAs): May be added if PPIs alone are insufficient.

Surgical Management

  • Localized duodenal gastrinomas: Enucleation or pancreas‑preserving duodenectomy when feasible.
  • Pancreatic gastrinomas: Distal pancreatectomy or Whipple procedure for larger lesions.
  • Metastatic disease: Liver-directed therapies (radiofrequency ablation, hepatic artery embolization) or cytoreductive surgery in selected patients.
  • MEN1 considerations: Because gastrinomas are often multifocal, complete resection is rarely possible; surgery is usually reserved for symptomatic or rapidly progressing tumors.

Medical Therapies for Tumor Control

  • Somatostatin analogues (octreotide, lanreotide): Inhibit gastrin release and can shrink neuroendocrine tumors.5
  • Targeted agents: Everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) are approved for progressive pancreatic neuroendocrine tumors; they may be used when surgery is not an option.
  • Peptide receptor radionuclide therapy (PRRT): 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor–positive tumors; shows durable disease control in many MEN 1 patients.

Lifestyle & Supportive Measures

  • Small, low‑fat meals to reduce duodenal irritation.
  • Avoidance of NSAIDs, aspirin, and alcohol, which exacerbate ulceration.
  • Calcium and vitamin D supplementation if hyperparathyroidism or malabsorption is present.
  • Regular bone‑density screening (DEXA) because of combined risk from acid excess and hyperparathyroidism.

Living with Zollinger‑Ellison Syndrome Secondary to MEN1

Monitoring & Follow‑up

  • Gastrin levels: Every 6–12 months while on PPIs; a rising trend may signal tumor progression.
  • Imaging: Annual EUS or MRI for MEN1 patients, or sooner if symptoms change.
  • Endoscopy: Repeat upper endoscopy every 1–2 years to assess ulcer healing.
  • MEN1 surveillance: Annual calcium/PTH, pituitary hormone panel, and fasting glucose/insulin checks.

Practical Daily Tips

  1. Medication adherence: Take PPIs 30 minutes before breakfast and dinner; never skip doses.
  2. Meal timing: Eat 4–5 small meals; avoid large fatty meals that stimulate acid production.
  3. Hydration: Aim for 2–3 L of water daily to offset diarrhea.
  4. Stress management: Chronic stress can increase gastric acid; consider meditation, yoga, or counseling.
  5. Vaccinations: Stay up‑to‑date on hepatitis B and pneumococcal vaccines, especially if liver metastases require systemic therapy.

Psychosocial Support

Living with a hereditary cancer syndrome can cause anxiety about family planning and disease progression. Genetic counseling, patient support groups (e.g., MEN1 Support Network), and mental‑health services are strongly recommended.

Prevention

Because MEN 1 is genetic, primary prevention of ZES is not possible, but early detection and intervention can prevent severe complications.

  • Genetic screening: Offer testing to first‑degree relatives of a confirmed MEN1 carrier.
  • Prophylactic surveillance: Begin annual biochemical (fasting gastrin, calcium) and imaging studies in mutation carriers by age 10–15.
  • Lifestyle: Avoid smoking and heavy alcohol use, which increase ulcer risk.

Complications

If untreated or inadequately controlled, ZES secondary to MEN1 can lead to serious health problems.

  • Refractory peptic ulcer disease – perforation or bleeding requiring emergency surgery.
  • Severe diarrhea and electrolyte abnormalities – can cause dehydration, renal insufficiency, or cardiac arrhythmias.
  • Gastro‑esophageal reflux disease (GERD) and Barrett’s esophagus – long‑term acid exposure.
  • Malabsorption & nutritional deficiencies – especially fat‑soluble vitamins (A, D, E, K) and iron.
  • Liver metastases – occur in 30–50 % of MEN1‑related gastrinomas; associated with reduced survival.
  • Secondary osteoporosis & fractures – from chronic acid load and hyperparathyroidism.
  • Pancreatic endocrine insufficiency – diabetes mellitus due to loss of normal islet cells after surgery or tumor burden.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you develop any of the following:
  • Sudden, severe abdominal pain that does not improve with usual medication.
  • Vomiting of blood (hematemesis) or coffee‑ground material.
  • Black, tarry stools (melena) indicating gastrointestinal bleeding.
  • Profuse watery diarrhea (>6 L/24 h) with dizziness, rapid heartbeat, or fainting.
  • High fever (>38.5 °C) combined with abdominal pain – possible perforated ulcer or infection.
  • Sudden onset of confusion, weakness, or seizures – could signal severe electrolyte disturbance (e.g., low potassium or magnesium).

Sources:

  1. Mayo Clinic. Zollinger‑Ellison Syndrome. https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellison-syndrome/symptoms-causes/syc-20373671
  2. National Institute of Health (NIH) – MEN1 Gene. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4539386/
  3. Cleveland Clinic. Zollinger‑Ellison Syndrome. https://my.clevelandclinic.org/health/diseases/21272-zollinger-ellison-syndrome
  4. Mayo Clinic. Treatment for Zollinger‑Ellison Syndrome. https://www.mayoclinic.org/diseases‑conditions/zollinger‑ellison-syndrome/diagnosis-treatment/drc-20373673
  5. Sun et al., “Somatostatin analogues in neuroendocrine tumors,” World Journal of Gastroenterology, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320656/
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References